Publications (230) Publications de CELIA OREJA GUEVARA

filter_list

2025

  1. Breaking the assumption: Disease-modifying therapy efficacy and relapse severity in relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 104

  2. Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years

    Journal of Neurology, Neurosurgery and Psychiatry

  3. Current challenges in secondary progressive multiple sclerosis: diagnosis, activity detection and treatment

    Frontiers in Immunology, Vol. 16

  4. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

    Brain, Vol. 148, Núm. 5, pp. 1459-1478

  5. Economic burden of secondary progressive multiple sclerosis: DISCOVER study

    BMC Health Services Research, Vol. 25, Núm. 1

  6. Efficient semi-supervised hierarchical training for segmenting choroidal vessels and other structures on OCT images of multiple sclerosis patients

    Biomedical Signal Processing and Control, Vol. 100

  7. Enhanced multiple sclerosis diagnosis using high-resolution 3D OCT volumes with synthetic slices

    Pattern Recognition Letters, Vol. 189, pp. 99-105

  8. Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis

    Neurology and Therapy, Vol. 14, Núm. 5, pp. 1975-1992

  9. Generics, Biosimilars and Follow-On Non-Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists

    European Journal of Neurology, Vol. 32, Núm. 4

  10. Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 12, Núm. 1, pp. e200349

  11. Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases

    Neurologia

  12. Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 82, Núm. 6, pp. 614-625

  13. The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors

    Frontiers in Immunology, Vol. 16

  14. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

    The New England journal of medicine, Vol. 392, Núm. 19, pp. 1883-1892

  15. Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook

    Therapeutic Advances in Neurological Disorders, Vol. 18

2024

  1. Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management

    Therapeutic Advances in Neurological Disorders, Vol. 17

  2. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  3. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

  4. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 84

  5. Esclerosis múltiple y mujer

    Libro blanco salud y género (Estudio de comunicación), pp. 149-167